EZH2 inactivation in RAS-driven myeloid neoplasms hyperactivates RAS-signaling and increases MEK inhibitor sensitivity
Open Access
- 15 February 2021
- journal article
- letter
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (5), 1521-1526
- https://doi.org/10.1038/s41375-021-01161-0
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor SensitivityCancer Cell, 2017
- Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive RasCold Spring Harbor Perspectives in Medicine, 2017
- Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung AdenocarcinomaInternational Journal of Biological Sciences, 2017
- Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemiaNature Medicine, 2016
- Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras.Leukemia, 2016
- Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemiaBlood Cancer Journal, 2016
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaThe New England Journal of Medicine, 2013
- Signaling Through RAS-RAF-MEK-ERK: from Basics to BedsideCurrent Medicinal Chemistry, 2007
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetesNature Genetics, 2003